Psychedelic ‘wonder drug’ of the ‘60s can improve Parkinson’s symptoms for weeks
NY Post, May 1, 2025
Psilocybin — the psychedelic compound that gave “magic mushrooms” their trippy reputation in the 1960s — is now showing serious promise for improving mood and motor function in people with Parkinson’s disease, according to a groundbreaking recent study.
‘I feel free’: how MDMA-assisted therapy helped Regan finally overcome her complex PTSD
ABC, April 28, 2025
Regan Ballantine was a sufferer of PTSD until she did MDMA therapy with Pax centre in Perth.
Listen as she describes the compelling story of her treatment, and how she finally feels “unburdened”.
“I was carrying something so heavy,” she says. “I just feel free.”
How Do Psychedelics Battle Stress? Scientists Find Their Influence Extends Beyond the Brain
Singularity Hub, April 25, 2025
The medicines disrupted communication between the brain and immune system to lower stress in mice.
Psychedelic Mushroom Market To Surpass $3.3 Billion By 2031, Report Predicts
Forbes, March 21, 2025
The use of psychedelic mushrooms is on the rise, and a new report confirms the expansion of the market with growing interest in psilocybin and its potential applications in therapy.
The Colorado psychedelic mushroom experiment has arrived
CBS News, March 19, 2025
Colorado regulators are issuing licenses for providing psychedelic mushrooms and are planning to authorise the state’s first “healing centers,” where the mushrooms can be ingested under supervision, in late spring or early summer.
Psychedelic therapy may soon be funded for veterans with PTSD, depression
ABC, March 4, 2025
The DVA plans to finalise its assessment guidelines for psychedelic-assisted therapies later this year.
Treatments like MDMA and psilocybin to be funded for veterans
ABC News, March 4, 2025
Australian veterans suffering from PTSD and depression will soon have access to a new form of treatment.
Innovative trial will use psilocybin to target relapse in opioid addiction
Imperial College, October 18, 2024
Imperial researchers will explore the potential for psilocybin therapy in drug recovery as part of a landmark trial.
A ‘first in the UK’ clinical trial exploring the use of psychedelics in addiction.
People Are Trying Magic Mushrooms for Depression — and Accidentally Meeting God
Rolling Stone, August 18, 2024
The article discusses how psychedelics are gaining attention as powerful spiritual tools amid setbacks in the medicalisation movement.
Psychedelic trial for compound headaches
The Australian, August 14, 2024
A rare condition could be treated with psilocybin, as an Australian study doubles down on the nation’s commitment to psychedelic medicine.
‘Danger zone’ for mental health, says global study
The Australian, August 14, 2024
The biggest-ever study of its kind, led by Australian psychiatrists, has found the incidence of mental ill-health in young people has risen by 50% in 15 years.
ASX Health Stocks: Psilocybin drug shows promise for fibromyalgia pain relief
Herald Sun, August 12, 2024
There’s new hope for fibromyalgia sufferers, with all patients in a pivotal trial of a new medicine reporting eased pain, improved sleep, and better quality of life.
Veterans and Lawmakers Lobby in Bipartisan Push for MDMA Therapy
New York Times, August 8, 2024
More than a half-century after federal regulators banned most psychedelic compounds, the Food and Drug Administration is nearing a decision on a novel treatment for post-traumatic stress disorder that pairs talk therapy with MDMA.
The end-of-life patients finding solace in magic mushrooms: ‘What life after life could be like’
The Guardian, August 7, 2024
Psychedelic medicines, like psilocybin, are currently the subject of intensive scientific research for their benefits in treating depression, PTSD and addiction. In cancer patients, like the studies Hartle came across, psilocybin has been shown to reduce existential distress.
Allaying the fears: MDMA with therapy is a medicine
Drug Science, August 6, 2024
Mind Medicine Australia’s Chair Peter Hunt AM co-authored an article with Professor David Nutt (Imperial College London), Tadeusz Hawrot (PAREA – Europe) and Dr Anne Schlag (Drug Science – UK) which analyses the recent decision of the FDA’s Advisory Committee on the proposed registration.
MDMA To Be Used As Trauma Treatment
The Project - CH10, July 1, 2024
Patients like Shannon Foster have struggled with PTSD resulting from childhood and intergenerational family trauma. After a decade of seeing a psychotherapist, earlier this month Shannon tried the new therapy in a Sydney clinic that has become the first in NSW to use MDMA to treat trauma, after it was approved by the TGA following clinical trials.
FDA advisors voted against MDMA therapy – researchers are still fighting for it
BBC, June 20, 2024
A vote against using MDMA as part of therapy for PTSD has provoked a powerful backlash among researchers who study psychedelic medicines.
Psychedelics therapy gets under way in NSW
Medical Republic, June 13, 2024
The state’s first patients have begun treatment with medically enhanced psychotherapy for PTSD and treatment-resistant depression.
Magic Mushrooms Get Canadian Export License in Psychedelic Race
BNN Bloomberg, June 3, 2024
Canada has licensed a startup to export psychedelics to Australia for patient use, the latest milestone in a contest to supply the potential growth of medical psychedelic medicines.
Psilocybin for dementia prevention?
Science Direct, June 1, 2024
The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.